{Reference Type}: Journal Article
{Title}: Variant ALK-fusion positive anaplastic large cell lymphoma (ALCL): A population-based paediatric study of the NHL-BFM study group.
{Author}: Luedersen J;Stadt UZ;Richter J;Oschlies I;Klapper W;Rosenwald A;Kalinova M;Simonitsch-Klupp I;Siebert R;Zimmermann M;Qi M;Nakel J;Scheinemann K;Knörr F;Attarbaschi A;Kabickova E;Woessmann W;Damm-Welk C;
{Journal}: Br J Haematol
{Volume}: 204
{Issue}: 5
{Year}: 2024 May 26
{Factor}: 8.615
{DOI}: 10.1111/bjh.19308
{Abstract}: Frequency, distribution and prognostic meaning of ALK-partner genes other than NPM1 in ALK-positive anaplastic large-cell lymphoma (ALCL) are unknown. Forty-nine of 316 ALCL diagnosed in the NHL-BFM study group showed no nuclear ALK expression suggestive of a variant ALK-partner; 41 were analysed by genomic capture high-throughput sequencing or specific RT-PCRs. NPM1::ALK was detected in 13 cases. Among the 28 patients with a non-NPM1::ALK-fusion partner, ATIC (n = 8; 29%) and TPM3 (n = 9; 32%) were the most common. Five of eight patients with ATIC::ALK-positive ALCL relapsed, none of nine with TPM3::ALK. Variant ALK-partners are rare and potentially associated with different prognoses.